An Overview of siRNA Delivery Strategies for Urological Cancers
The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) see...
Main Authors: | Nadia Halib, Nicola Pavan, Carlo Trombetta, Barbara Dapas, Rossella Farra, Bruna Scaggiante, Mario Grassi, Gabriele Grassi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/4/718 |
Similar Items
-
Strategies for Delivery of siRNAs to Ovarian Cancer Cells
by: Rossella Farra, et al.
Published: (2019-10-01) -
siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells
by: Saiedeh Razi Soofiyani, et al.
Published: (2017-12-01) -
Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness
by: Rossella Farra, et al.
Published: (2018-03-01) -
Design of siRNA Therapeutics from the Molecular Scale
by: Christina Chan, et al.
Published: (2013-03-01) -
Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery
by: Wanyi Tai
Published: (2019-06-01)